Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 5.5% year on year to $247.2 million. On the other hand, the company’s full-year revenue guidance of $543 million at the midpoint came in 49.5% below analysts’ estimates. Its GAAP loss of $0.30 per share was 32% above analysts’ consensus estimates.

Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Tandem Diabetes Care’s first quarter results were met with a positive market reaction, reflecting the company’s ability to exceed Wall Street’s revenue and GAAP loss expectations. Management pointed to the successful ramp of new product launches, the initial rollout of its pay-as-you-go (PayGo) pharmacy model, and early international direct channel expansion as key drivers. CEO John F. Sheridan emphasized, “We are bringing a great deal of new technology and business model changes that we believe will really help us grow new starts from MDI [multiple daily injection] patients.” The quarter also saw improvements in operational efficiency, supported by cost discipline and enhanced sales infrastructure.

Looking ahead, Tandem Diabetes Care’s forward guidance is shaped by several strategic transitions and pipeline milestones. Management expects the continued adoption of the PayGo pharmacy model to be a central growth lever, while expanded product availability—including Android support and pregnancy indication for Control-IQ+—should fuel incremental demand. CFO Leigh A. Vosseller noted, “Nothing has changed our conviction in our ability to grow and scale [the pharmacy model] across the year.” However, ongoing infusion set supply constraints and the phased commercialization of new offerings like Mobi Tubeless will require close monitoring, as these dynamics are expected to influence sales cadence and margin improvement throughout the year.

Key Insights from Management’s Remarks

Management credited Q1’s operational gains to product pipeline momentum, early PayGo channel adoption, and international go-direct initiatives, while also highlighting ongoing supply chain and pricing dynamics.

• PayGo pharmacy model rollout: The launch of PayGo in the U.S. pharmacy channel, covering t:slim and Mobi pump supplies, began in March and now represents roughly 40% formulary coverage. Management described the transition as an end-to-end change in prescription and fulfillment workflows. Early adoption was within the company’s expected range, and leadership remains confident in scaling participation as the year progresses. This model is anticipated to lower upfront patient costs and improve recurring supply margins for Tandem Diabetes Care.
• Product innovation and launches: The company expanded its Tandem Mobi system, making it fully compatible with Android smartphones in the U.S. In addition, the t:slim X2 and Mobi systems received the first FDA clearance for use in pregnant women with type 1 diabetes. International launches are being prepared for both Mobi and the Abbott FreeStyle Libre 3+ CGM (continuous glucose monitoring) integration. These updates are designed to broaden market reach and differentiate the product portfolio.
• International go-direct expansion: Tandem Diabetes Care launched direct commercial operations in the UK, Switzerland, and Austria, moving away from distributor-based models. Management expects this strategy to strengthen healthcare provider relationships, improve average selling prices (ASP), and drive margin gains. Early feedback from markets with direct operations has been positive, and the company anticipates expanding this approach to additional countries in the coming years.
• Gross margin and cost discipline: Gross margin improved year-over-year, driven by pricing discipline, product cost reductions, and more direct sales channels internationally. Operating expenses were kept flat despite increased investments in global growth, and stock-based compensation as a percentage of sales declined. The company generated positive free cash flow and improved adjusted EBITDA margin, reflecting a sharper focus on profitability.
• Supply chain and competitive environment: Management flagged ongoing infusion set supply shortages as a modest but persistent headwind, emphasizing efforts to offer alternative solutions to minimize patient impact. The competitive landscape remains intense, with no major shifts noted in the quarter. Leadership reiterated its focus on differentiation through technology, expanded access, and a growing product pipeline.

Drivers of Future Performance

Tandem Diabetes Care’s outlook is anchored by its ongoing pharmacy channel transition, new product launches, and international direct strategy, with supply chain risks and market competition as key variables.

• Pharmacy channel expansion: Management expects the PayGo pharmacy model to increase recurring supply revenue and improve margin profile as more patients and prescribers transition from traditional durable medical equipment (DME) channels. Success depends on accelerating formulary coverage, streamlining physician workflows, and converting both new and existing customers to pharmacy fulfillment.
• Pipeline and regulatory milestones: The company anticipates commercial launches for several products, including the Mobi Tubeless system pending FDA clearance and wider rollout of CGM integrations. While Mobi Tubeless is not expected to contribute materially in 2026, its phased launch could influence competitive positioning and future growth, especially as the tubeless market segment expands.
• Supply and competitive risks: Persistent infusion set shortages are expected to modestly impact sales through the first half of the year, with management aiming for resolution by year-end. The diabetes technology space remains highly competitive, and the pace of new customer adoption, especially among type 2 diabetes patients and pharmacy channel converts, will be closely watched.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of PayGo pharmacy channel adoption and its impact on recurring supply revenue, (2) the resolution of infusion set supply constraints and resulting effects on sales growth, and (3) the regulatory progress and early feedback for Mobi Tubeless and international direct channel expansion. Advances in CGM integration and coverage for type 2 diabetes patients will also be important indicators for sustained momentum.

Tandem Diabetes currently trades at $20.62, up from $18.49 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.